MedTrace Logo

SF2000SD Clinical Trial in Zambia

NCT02941159 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2017-11-17

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of SF2000SD in adult male healthy volunteers

Conditions

  • Good Health

Interventions

BIOLOGICAL

SF2000SD

This is an intergrase inhibitor

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • National Institute for Scientific and Industrial Research

    collaborator UNKNOWN

  • University of Zambia

    collaborator OTHER

  • National AIDS/TB/STIs Council of Zambia

    collaborator UNKNOWN

  • Copperbelt University of Zambia

    collaborator UNKNOWN

  • Dr Ludwick Sondashi Formular Clinic

    collaborator UNKNOWN

  • Tropical Diseases Research Centre, Zambia

    lead OTHER_GOV

Principal Investigators

  • Ray Handema, PhD · Tropical Diseases Research Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-11-30
Completion
2018-02-28

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02941159 on ClinicalTrials.gov